Cardiotoxicity testing using pluripotent stem cell‐derived human cardiomyocytes and state‐of‐the‐art bioanalytics: a review
Journal of Applied Toxicology2011Vol. 31(3), pp. 191–205
Citations Over TimeTop 10% of 2011 papers
Carl‐Fredrik Mandenius, Daniella Steel, Noor Fatima, Thomas Meyer, Elmar Heinzle, Julia Asp, Sarina Arain, Udo Kraushaar, Susanne Bremer, Reiner Class, Peter Sartipy
Abstract
In this article, recent progress in cardiotoxicity testing based on the use of immortalized cell lines or human embryonic stem cell (hESC) derived cardiomyocytes in combination with state-of-the-art bioanalytical methods and sensors is reviewed. The focus is on hESC-derived cells and their refinement into competent testing cells, but the access and utility of other relevant cell types are also discussed. Recent developments in sensor techniques and bioanalytical approaches for measuring critical cardiotoxicity parameters are highlighted, together with aspects of data evaluation and validation. Finally, recommendations for further research are given.
Related Papers
- → Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin(2018)27 cited
- → Cardiotoxicity Induced by Anticancer Drugs—the Role of Biomarkers(2016)1 cited
- The cardiotoxicity of anticancer agents.(1982)
- → Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients(2023)2 cited
- In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.(2001)